Biotech News

BioCardia Reports Third Quarter 2026 Business Highlights and Financial Results

BioCardia (BCDA)BioCardiaEarnings

BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the third quarter 2026 and filed its quarterly report on Form 10-Q for the three and nine months ended September 30, 2026 with the Securities and Exchange Commission. The Company will also hold a conference call at 4:30 PM ET today in which it will discuss business highlights. Following management’s formal remarks, there will be a question-and-answer session.

Related news

BioCardia

Cardiovascular Cell Therapy Company BioCardia develops cellular and cell-derived therapies for cardiovascular and pulmonary diseases. Its platform includes autologous CardiAMP and allogeneic CardiALLO cell therapies, supported by the Helix delivery and Morph vascular-navigation technologies. CardiAMP Heart Failure Program CardiAMP Cell...

Recent company news

Stock data

Close
0.77 USD
Market cap
10.24M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States